Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3461-3475

  Sulkes, Aaron ^a   Benner, Steven E ^a   Canetta, Renzo M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; UFT;

ADULT; AGED; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STOMATITIS; VOMITING;

EID: 0031727480     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3461     Document Type: Review

References (72)

1. Hiller SA, Juk RA, Lidak MYU: Analogs of pyrimidine nucleosides. Dokl Akad Nauk SSSR 176:332-335, 1967
2. Kurihara M: Clinical experience with UFT in Japan, in Rustum YM (ed): Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. New York, NY, Plenum, 1993, pp 243-250
3. Blokhina NG, Vozny EK, Garin AM: Results of treatment of malignant tumors with ftorafur. Cancer 30:390-392, 1972
4. Friedman MA, Ignoffo RJ: A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NAC-148958). Cancer Treat Rev 7:205-213, 1980
5. Valdivieso M, Bodey GP, Gottlieb JA: Clinical evaluation of ftorafur (pyrimidine-deoxyribose N1-2′-furanidyl-5-fluorouracil). Cancer Res 36: 1821-1824, 1976
6. Anttila MI, Sotaniemi EA, Kairaluoma MI, et al: Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10:150-153, 1983
7. Fujii S, Ikenaka K, Fukushima M, et al: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5 fluorouracil. Gann 69:763-772, 1978
8. Fujii S, Kitano S, Ikenaka K, et al: Effect of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70:209-214, 1979
9. Taguchi T: Clinical application of biochemical modulation in cancer chemotherapy: Biochemical modulation for 5FU. Oncology 54:12-18, 1997
10. Chabner BA: Pyrimidine antagonists, in Chabner BA (ed): Pharmacologic Principles of Cancer Treatment. Philadelphia, PA, Saunders, 1982, pp 183-212
11. Takahashi N, Nitta A, Saitou T, et al: The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in the patients with gastric and colorectal cancer after oral administration of UFT. Jpn J Cancer Chemother 15:2319-2323, 1988
12. Tsujimoto T, Sakai S, Murata M: Concentrations of 5FU in the tissue and serum of patients with head and neck malignant tumors by preoperative administration of UFT. Jpn J Cancer Chemother 10:78-83, 1983
13. Suemasu K, Azuma Y, Nomoto M: Concentration of 5FU level in the tissue and blood of patients with breast cancer by preoperative administration of UFT. Jpn J Cancer Chemother 9:667-671, 1982
14. Spiegelman S, Sawyer R, Nayak R: Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into DNA via metabolic modulation. Proc Natl Acad Sci U S A 77:4966-4970, 1980
15. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
16. Petrelli N, Douglass HO Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
17. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 6:469-475, 1988
18. Keyomarsi K, Moran RG: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46:5229-5235, 1986
19. McGuire B, Sia L, Haynes J, et al: Absorption kinetics of orally administered leucovorin calcium. NCI Monogr 5:47-56, 1987
20. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal carcinoma. J Clin Oncol 12:14-20, 1994
21. Hansen RM, Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668-674, 1996
22. Watanabe K, Sato H, Matsuzaki T, et al: Cooperative phase I study of UFT. J Jpn Soc Cancer Ther 14:281, 1979 (abstr 251)
23. Yokoyama T, Nakao I, Ohashi Y, et al: Clinical evaluation of UFT. J Jpn Soc Cancer Ther 14:281-282, 1979 (abstr 252)
24. Fukui Y, Imabayashi N, Nishi M, et al: Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Gan To Kagaku Ryoho 7:2124-2129, 1980
25. Majima H: Phase I and preliminary phase II study of coadministration of uracil and FT-207 (UFT therapy). Gan To Kagaku Ryoho 7:1383-1387, 1980
26. Watanabe H, Yamamoto S, Naito T: Clinical results of oral UFT therapy under cooperative study. Gan To Kagaku Ryoho 7:1588-1596, 1980
27. Taguchi T: Phase I study of UFT (uracil plus futraful preparation). Gan To Kagaku Ryoho 7:966-972, 1980
28. Takino T: Clinical studies on the chemotherapy of advanced cancer with UFT (uracil plus futraful preparation). Gan To Kagaku Ryoho 7:1804-1812, 1980
29. Murakami M, Ota K: Clinical results of UFT therapy for malignant tumors under cooperative study (phase II study). Gan To Kagaku Ryoho 7:1579-1586, 1980
30. Nakajima O, Ihara K, Isoda T, et al: Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl) 5-fluorouracil and uracil (UFT). Gan To Kagaku Ryoho 7:1558-1568, 1980
31. Sadahiro S, Mukai M, Tokunaga N, et al: Preliminary study on the new optimal dosage schedule for oral UFT. Proc Amer Soc Clin Oncol 16:207, 1997 (abstr 726)
32. Pazdur R, Lassere Y, Diaz-Canton E, et al: Phase I trials of uracil-tegafur (UFT) using 5- and 28-day administration schedules: Demonstration of schedule-dependent toxicities. Anticancer Drugs 7:728-733, 1996
33. Saltz L, Young C, Currie V, et al: Phase I and clinical pharmacologic studies of oral UFT alone and with oral leucovorin (LV). Proc Amer Soc Clin Oncol 12:149, 1993 (abstr 394)
34. Muggia FM, Wu X, Spicer D, et al: Phase I and pharmocokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 2:1461-1467, 1996
35. Harris BE, Song R, Soong S, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil level with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
36. Rustum YM, Cao S, Creaven PJ, et al: Phase I clinical trials and pharmacokinetics of uracil-ftorafur combination (UFT) + leucovorin (LV) in patients with advanced colorectal cancer. Ther Res 14:241-249, 1993
37. Spicer D, Muggia F, Tulpule A, et al: Phase I circadian dosing of daily oral uracil (U) plus 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) with leucovorin (LV). Proc Amer Assoc Cancer Res 10:342, 1991 (abstr)
38. González Barón M, Colmenarejo A, Feliu J, et al: Preliminary results of phase I clinical trial. UFT modulated by folinic acid (PO) in the treatment of advanced colorectal cancer. Ther Res 13:451-458, 1992
39. Nogué Aliguer M, Saigi Grau E: Protracted treatment with UFT and leucovorin by oral way. Oncologia (Spain) 15:114-116, 1992
40. Pazdur R, Lassere Y, Diaz-Canton E, et al: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-Day schedule. Invest New Drugs 15:123-128, 1997
41. Pazdur R, Lassere Y, Díaz-Canton E, et al: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-Day schedule. Cancer Invest 16:145-151, 1998
42. Meropol NJ, Rustum YM, Petrelli NJ, et al: A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37:581-586, 1996
43. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333-338, 1988
44. Malik STA, Talbot D, Clarke PI, et al: Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 62:1023-1025, 1990
45. Sanchiz F, Milla A: Tegafur UFT in advanced colorectal cancer, a phase II study. Anticancer Res 5:1122, 1988 (abstr 332)
46. Saltz LB, Leichman CG, Young CW, et al: A fixed-ratio combination of uracil and ftorafur (UFT) with low-dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75:782-785, 1995
47. González Barón M, Feliu J, de la Gandara I, et al: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31A:2215-2219, 1995
48. González Barón M, Feliu J, Garcia Girón C, et al: UFT® modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 54:24-29, 1997 (suppl 1)
49. Abad A, Navarro M, Sastre J, et al: Phase II continuous UFT plus folinic acid in elderly patients with colorectal cancer. Proc Amer Soc Clin Oncol 16: 280, 1997 (abstr 994)
50. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994
51. Pazdur R, Patt Y, Ajani J, et al: Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients. Proc Amer Soc Clin Oncol 16:270, 1997 (abstr 959)
52. Sanchiz F, Milla A: Tegafur-uracil (UFT) plus folinic acid in advanced rectal-cancer. Jpn J Clin Oncol 24:322-326, 1994
53. Gonzalez Baron M, Feliu J, De la Gandara I, et al: Phase II trial of uracil-tegafur (UFT), leucovorin (LV) and mitomycin C in advanced colorectal cancer. Ann Oncol 5:53, 1994 (suppl 8; abstr 261)
54. Ikeda E, Kodaira S, Teramoto T, et al: Optimal dose of UFT + MCC combination chemotherapy for advanced colorectal cancer -Phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration: Study group of UFTM therapy for advanced colorectal cancer. Gan To Kagaku Ryoho 21:1291-1298, 1996
55. Mori T, Takahashi K, Yasuno M: The consistent chemotherapy for the patients with advanced colorectal cancer consisting of 5-FU, low-dose CDDP and UFT. Seventh International Congress of Anti-Cancer Treatment 7:73, 1997
56. Nakazato H, Kolka A, Saji S, et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: A prospective randomized clinical trial. Proc Amer Soc Clin Oncol 16:279, 1997 (abstr 990)
57. Kikuchi K, Kjunii Y, Kunitomo K: Treatment with UFT as surgical adjuvant chemotherapy for carcinoma of large intestine. Jpn J Cancer Chemo 17:663-670, 1990
58. Fujii M, Kochi M, Sawa H, et al: Preoperative and postoperative adjuvant chemotherapy for colorectal cancer - Results of 5-year survival using UFT. A pilot study. J Jpn Soc Cancer Ther 30:584-594, 1995
59. Nishimura G, Michiwa Y, Yagi H, et al: Evaluation of preoperative chemotherapy for colorectal cancer. Gan To Kagaku Ryoho 23:69-74, 1996
60. Mitomi T, Tsuchiya S, Hiki Y: A randomized controlled study on adjuvant chemotherapy with UFT in curatively resected colorectal cancer. Proc Amer Soc Clin Oncol 12:225, 1993 (abstr 690)
61. Maetani S: Multicenter clinical trial of UFT with FT for patients with colorectal cancer. Ther Res 14:226-232, 1993
62. Takashima S, Tomita F, Saito H, et al: Clinical effect of postoperative adjuvant chemotherapy for advanced colorectal cancer -Comparisons between tegafur (FT) and UFT. Gan To Kagaku Ryoho 18:2315-2324, 1991
63. Okuda M, Teramoto T, Watanabe M, et al: Adjuvant chemotherapy with mitomycin C, tegafur and UFT in colorectal cancer. J Jpn Soc Coloproctol 48:120-128, 1995
64. Abad A, Lopez MP, Baiste-Alentom E, et al: Oral adjuvant chemotherapy in stage II (B2-3) and III (C) colon cancer. Second Educational Convention of the European School of Oncology, Vienna, Austria, 1996. Eur J Cancer 32A:526, 1996 (abstr 132)
65. Pazdur R, Covington WP, Brown NS, et al: Comparative steady-state pharmocokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU). Proc Amer Soc Clin Oncol 15:474, 1996 (abstr 1498)
66. Rustum YM: Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 54:7-11, 1997 (suppl 1)
67. Okabe H, Toko T, Saito H, et al: Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral 1-leucovorin. Anticancer Res 17:157-164, 1997
68. Takechi T, Saito H, Oie S, et al: Synergistic interaction between UFT and cisplatin in human solid tumor-xenografts. Proc Amer Assoc Cancer Res 34:282, 1993 (abstr 1676)
69. Giacchetti S, Zidani R, Perpoint B, et al: Phase III trial of 5 fluorouracil, folinic acid with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc Amer Soc Clin Oncol 16:229, 1997 (abstr 805)
70. Taguchi T: UFT (tegafur/uracil) - Biochemical modulation of 5-FU. Chin Med J 110:294-296, 1997
71. Rustum YM, Cao S, Shirasaka T, et al: A new 5 fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II clinical trials. Proc Amer Soc Clin Oncol 16:227, 1997 (abstr 799)
72. Peters GJ, Van Groeningen CJ, Schomage JH, et al: Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil-based antineoplastic agent. Proc Amer Soc Clin Oncol 16:227, 1997 (abstr 800)